56 related articles for article (PubMed ID: 38745749)
1. Oncolytic virus V937 in combination with PD-1 blockade therapy to target immunologically quiescent liver and colorectal cancer.
Tran TQ; Grein J; Selman M; Annamalai L; Yearley JH; Blumenschein WM; Sadekova S; Chackerian AA; Phan U; Wong JC
Mol Ther Oncol; 2024 Jun; 32(2):200807. PubMed ID: 38745749
[TBL] [Abstract][Full Text] [Related]
2. Mechanistic Modeling of a Novel Oncolytic Virus, V937, to Describe Viral Kinetic and Dynamic Processes Following Intratumoral and Intravenous Administration.
Parra-Guillen ZP; Freshwater T; Cao Y; Mayawala K; Zalba S; Garrido MJ; de Alwis D; Troconiz IF
Front Pharmacol; 2021; 12():705443. PubMed ID: 34366859
[TBL] [Abstract][Full Text] [Related]
3. Intratumoral oncolytic virus V937 plus ipilimumab in patients with advanced melanoma: the phase 1b MITCI study.
Curti BD; Richards J; Hyngstrom JR; Daniels GA; Faries M; Feun L; Margolin KA; Hallmeyer S; Grose M; Zhang Y; Li A; Andtbacka RHI
J Immunother Cancer; 2022 Dec; 10(12):. PubMed ID: 36564126
[TBL] [Abstract][Full Text] [Related]
4. Phase 1, open-label, dose-escalation study on the safety, pharmacokinetics, and preliminary efficacy of intravenous Coxsackievirus A21 (V937), with or without pembrolizumab, in patients with advanced solid tumors.
Rudin CM; Pandha HS; Zibelman M; Akerley WL; Harrington KJ; Day D; Hill AG; O'Day SJ; Clay TD; Wright GM; Jennens RR; Gerber DE; Rosenberg JE; Ralph C; Campbell DC; Curti BD; Merchan JR; Ren Y; Schmidt EV; Guttman L; Gupta S
J Immunother Cancer; 2023 Jan; 11(1):. PubMed ID: 36669791
[TBL] [Abstract][Full Text] [Related]
5. A phase 1b single-arm trial of intratumoral oncolytic virus V937 in combination with pembrolizumab in patients with advanced melanoma: results from the CAPRA study.
Silk AW; O'Day SJ; Kaufman HL; Bryan J; Norrell JT; Imbergamo C; Portal D; Zambrano-Acosta E; Palmeri M; Fein S; Wu C; Guerreiro L; Medina D; Bommareddy PK; Zloza A; Fox BA; Ballesteros-Merino C; Ren Y; Shafren D; Grose M; Vieth JA; Mehnert JM
Cancer Immunol Immunother; 2023 Jun; 72(6):1405-1415. PubMed ID: 36445410
[TBL] [Abstract][Full Text] [Related]
6. ICAM-1 promotes cancer progression by regulating SRC activity as an adapter protein in colorectal cancer.
Lim EJ; Kang JH; Kim YJ; Kim S; Lee SJ
Cell Death Dis; 2022 Apr; 13(4):417. PubMed ID: 35487888
[TBL] [Abstract][Full Text] [Related]
7. A Three-Dimensional Organoid Model of Primary Breast Cancer to Investigate the Effects of Oncolytic Virotherapy.
Carter ME; Hartkopf AD; Wagner A; Volmer LL; Brucker SY; Berchtold S; Lauer UM; Koch A
Front Mol Biosci; 2022; 9():826302. PubMed ID: 35223990
[No Abstract] [Full Text] [Related]
8. Patient-Derived Organoids in Precision Medicine: Drug Screening, Organoid-on-a-Chip and Living Organoid Biobank.
Zhou Z; Cong L; Cong X
Front Oncol; 2021; 11():762184. PubMed ID: 35036354
[TBL] [Abstract][Full Text] [Related]
9. Clinical Responses of Oncolytic Coxsackievirus A21 (V937) in Patients With Unresectable Melanoma.
Andtbacka RHI; Curti B; Daniels GA; Hallmeyer S; Whitman ED; Lutzky J; Spitler LE; Zhou K; Bommareddy PK; Grose M; Wang M; Wu C; Kaufman HL
J Clin Oncol; 2021 Dec; 39(34):3829-3838. PubMed ID: 34464163
[TBL] [Abstract][Full Text] [Related]
10. Novel oncolytic adenovirus expressing enhanced cross-hybrid IgGA Fc PD-L1 inhibitor activates multiple immune effector populations leading to enhanced tumor killing in vitro, in vivo and with patient-derived tumor organoids.
Hamdan F; Ylösmäki E; Chiaro J; Giannoula Y; Long M; Fusciello M; Feola S; Martins B; Feodoroff M; Antignani G; Russo S; Kari O; Lee M; Järvinen P; Nisen H; Kreutzman A; Leusen J; Mustjoki S; McWilliams TG; Grönholm M; Cerullo V
J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34362830
[TBL] [Abstract][Full Text] [Related]
11. Targeting Innate Immunity in Cancer Therapy.
Rameshbabu S; Labadie BW; Argulian A; Patnaik A
Vaccines (Basel); 2021 Feb; 9(2):. PubMed ID: 33572196
[TBL] [Abstract][Full Text] [Related]
12. α-Ketoglutarate attenuates Wnt signaling and drives differentiation in colorectal cancer.
Tran TQ; Hanse EA; Habowski AN; Li H; Ishak Gabra MB; Yang Y; Lowman XH; Ooi AM; Liao SY; Edwards RA; Waterman ML; Kong M
Nat Cancer; 2020 Mar; 1(3):345-358. PubMed ID: 32832918
[TBL] [Abstract][Full Text] [Related]
13. Current concepts in tumour-derived organoids.
Porter RJ; Murray GI; McLean MH
Br J Cancer; 2020 Oct; 123(8):1209-1218. PubMed ID: 32728094
[TBL] [Abstract][Full Text] [Related]
14. Patient-derived pancreatic tumour organoids identify therapeutic responses to oncolytic adenoviruses.
Raimondi G; Mato-Berciano A; Pascual-Sabater S; Rovira-Rigau M; Cuatrecasas M; Fondevila C; Sánchez-Cabús S; Begthel H; Boj SF; Clevers H; Fillat C
EBioMedicine; 2020 Jun; 56():102786. PubMed ID: 32460166
[TBL] [Abstract][Full Text] [Related]
15. Oncolytic Viruses and the Immune System: The Dynamic Duo.
Lemos de Matos A; Franco LS; McFadden G
Mol Ther Methods Clin Dev; 2020 Jun; 17():349-358. PubMed ID: 32071927
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
